ArticleCPT: pharmacometrics & systems pharmacology2014
Modeling and simulation of count data.
Article in CPT: pharmacometrics & systems pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- An Innovative Pharmacometric Approach for the Simultaneous Analysis of Frequency, Duration and Severity of Migraine Events.Pharmaceutical research · 2020Trial
- Population pharmacokinetics-pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex.Journal of pharmacokinetics and pharmacodynamics · 2018Trial
- Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures.Clinical pharmacokinetics · 2018Trial
- Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer.Clinical pharmacology and therapeutics · 2026Article
- Analyzing Pharmacodynamic Count Data That Rapidly Decrease to Zero.CPT: pharmacometrics & systems pharmacology · 2026Article
- Use of PopPK and E-R Analyses toward Explaining Causal Link Between ADAMTS13 in Recombinant vs. Plasma-Based Therapies and Clinical Effects in cTTP.Clinical pharmacology and therapeutics · 2025Article
- A tutorial on pharmacometric Markov models.CPT: pharmacometrics & systems pharmacology · 2025Article
- Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Review
- Automated Poisson regression exposure-response analysis for binary outcomes with PoissonERM.CPT: pharmacometrics & systems pharmacology · 2024Article
- Exposure-Response Relationship between VWF/FVIII Activity and Spontaneous Bleeding Events Following Recombinant VWF Prophylaxis in Severe VWD.TH open : companion journal to thrombosis and haemostasis · 2024Article
- Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII.Clinical pharmacokinetics · 2021Article
- Novel nomogram-based integrated gonadotropin therapy individualization in in vitro fertilization/intracytoplasmic sperm injection: A modeling approach.Clinical and experimental reproductive medicine · 2021Article
- A comparison study on modeling of clustered and overdispersed count data for multiple comparisons.Journal of applied statistics · 2021Review
- Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis.Journal of pharmacokinetics and pharmacodynamics · 2019Article
- Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components.British journal of clinical pharmacology · 2019Observational
- Kernel-Based Visual Hazard Comparison (kbVHC): a Simulation-Free Diagnostic for Parametric Repeated Time-to-Event Models.The AAPS journal · 2017Article
- PharmML in Action: an Interoperable Language for Modeling and Simulation.CPT: pharmacometrics & systems pharmacology · 2017Article
- Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.Journal of pharmacokinetics and pharmacodynamics · 2017Article
- Effects of research complexity and competition on the incidence and growth of coauthorship in biomedicine.PloS one · 2017Article
- New generalized poisson mixture model for bimodal count data with drug effect: An application to rodent brief-access taste aversion experiments.CPT: pharmacometrics & systems pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Count data, or number of events per time interval, are discrete data arising from repeated time to event observations. Their mean count, or piecewise constant event rate, can be evaluated by discrete probability distributions from the Poisson model family. Clinical trial data characterization often involves population count analysis. This tutorial presents the basics and diagnostics of count modeling and simulation in the context of pharmacometrics. Consideration is given to overdispersion, underdispersion, autocorrelation, and inhomogeneity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.